GLOW peptide: what is in it and does it work?

What is in GLOW?

GLOW contains GHK-Cu, BPC-157, and TB-500 (thymosin beta-4). Products sold as GLOW usually list GHK-Cu, BPC-157, and TB-500 in one vial, but the ratio and total amount differ from seller to seller, and some labels add other ingredients. Research-chemical products are not made or tested to a drug standard, so what a vial actually contains is not verified. PeptideAgent does not name or link sellers.

Also searched as: Glow peptide blend; GLOW blend; GHK-Cu, BPC-157, and TB-500 blend.

Grades and statuses come from each peptide's own record and update with it. Grades follow the methodology.

Why are these peptides combined in GLOW?

The pitch for GLOW is that three repair signals add up: GHK-Cu for collagen and skin remodeling, BPC-157 for blood vessel growth and soft tissue healing, and TB-500 for cell migration and wound closure. Each claim traces back to laboratory and animal work on a single peptide, not to any study of the three together.

The skin half of the story comes from topical GHK-Cu, where small cosmetic studies reported firmer skin and fewer fine lines. The healing half comes from rodent tendon, muscle, and wound models of BPC-157 and thymosin beta-4. A 2026 review of peptides marketed for injury recovery found that many unapproved peptides look favorable in animal models while rigorous human safety data remain scarce. [3] [4] [7] [9]

Has GLOW been studied?

No published study has tested GLOW, or any combination of GHK-Cu, BPC-157, and TB-500, in humans or animals. PubMed indexes no trial of the three together as of the last verification date.

The single ingredients do not close that gap. There is no human trial of injected GHK-Cu for any indication; its human data are topical cosmetic studies. A 2025 systematic review of BPC-157 found 35 preclinical studies and one small retrospective human report, and no clinical safety data. Full-length thymosin beta-4 has small phase 1 and phase 2 human trials (IV safety, eye drops for dry eye, topical gel for skin ulcers). None tested injected TB-500 for injury healing.

Mixing peptides in one vial also raises questions nobody has studied: whether they stay stable together, whether they interact, and whether their side effects add up. [4] [5] [8] [9] [14] [15]

What each ingredient has shown alone

• GHK-Cu (human observational evidence). Copper binding three amino acid peptide with decades of skin and wound data: lawful and well studied in skin cosmetics, unapproved and untested as an injection.
• BPC-157 (animal-only evidence). A 15 amino acid peptide with strong animal healing data, no randomized human trial in PubMed, and a shifting FDA compounding status.
• TB-500 (thymosin beta-4) (animal-only evidence). Copy or fragment of the repair protein thymosin beta-4: strong animal data, small human trials of the full protein, no trial of injected TB-500; WADA banned.

GLOW results and before and after claims

Searches for GLOW before and after photos are common, but photos are not evidence. They are not controlled for lighting, skin care, weight change, time, or selection of the best results, and the product in the photo is not verified.

The measured human outcomes closest to the GLOW claims come from topical GHK-Cu cosmetic studies, which reported tighter skin, better elasticity, and fewer fine lines after weeks of daily application. Those studies are small, many were run or summarized by the peptide's discoverer, and none used an injection. No human study has measured skin, hair, or healing outcomes after injecting GLOW or its peptides.

A 2026 sports medicine review also names the placebo effect as a driver of perceived peptide results and notes that social media amplifies it. Until a controlled trial exists, reported results for GLOW are anecdotes. [4] [8] [9]

What are the side effects of GLOW?

There is no safety study of GLOW. Its risks are the unknowns of each ingredient plus the unknowns of the product: a systematic review found no clinical safety data at all for BPC-157, and there are no systematic human safety data for injected GHK-Cu or TB-500.

The problems most often reported with injected peptides are injection site pain, redness, and irritation. Reviews also raise a theoretical concern that peptides which promote new blood vessel growth and cell migration could affect existing tumors. That has not been shown in humans, and it has not been ruled out.

Product risk may be larger than drug risk. The BPC-157 systematic review warns that adverse effects are possible from unregulated manufacturing and contamination, and a vial of three peptides multiplies the chances of a wrong amount or a wrong ingredient. [3] [6] [8] [9]

Reported for each ingredient

From each peptide's record. These were reported for the peptide alone, not for the blend. Absence of data is not evidence of safety.

Is GLOW legal?

A blend inherits the strictest status among its ingredients, because a mixed product is only as lawful as its least lawful component. For GLOW that is GHK-Cu: no lawful path. At least one ingredient cannot be lawfully compounded or prescribed, so no licensed pharmacy can lawfully make the mix.

• GHK-Cu regulatory timeline (Removed from Category 2 (Apr 2026))
• BPC-157 regulatory timeline (Under FDA review)
• TB-500 (thymosin beta-4) regulatory timeline (Under FDA review)

Why blends like this are sold as research chemicals

A drug for human use in the United States has to be FDA approved or lawfully compounded by a licensed pharmacy for a named patient under a prescription. This blend can be neither, so vials sold under its name carry labels such as “for research use only” or “not for human consumption”. That label does not make a product lawful to inject, and it means no one has checked the vial for identity, purity, sterility, or amount. [11]

WADA status

BPC-157 and TB-500 (thymosin beta-4) are prohibited at all times on the WADA list, so any product containing them is prohibited for athletes subject to anti-doping testing.

State rules: peptide laws by state. All FDA actions: regulatory tracker.

What does GLOW cost, and what can a provider lawfully offer?

There is no lawful compounded price for GLOW, because there is no lawful way to compound it. A 503A pharmacy may compound from a bulk drug substance only if the substance has a USP or NF monograph, is a component of an FDA approved drug, or appears on the 503A bulks list. Injectable GHK-Cu meets none of those conditions: its nomination was withdrawn, it is not on the bulks list, and it was not reviewed by the Pharmacy Compounding Advisory Committee in July 2026. A mix is only as eligible as its least eligible ingredient.

BPC-157 and TB-500 were recommended for the 503A bulks list at the July 2026 advisory committee meeting, but that advice does not change the law until FDA publishes a final rule. Even after a rule, a GLOW-style mix would still contain injectable GHK-Cu.

Topical GHK-Cu is different. Cosmetic creams and serums are lawfully sold without FDA premarket approval as long as they make no drug claims, and that is also the form with the human skin data. Clinic and research-chemical prices for GLOW vials are not a lawful price, and research-chemical products are labeled not for human use. [10] [11] [12]

• GHK-Cu cost by channel
• BPC-157 cost by channel
• TB-500 (thymosin beta-4) cost by channel
• Rules by state
• Verified provider directory

What's actually offered, and what that means for you

Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. That does not make GLOW lawful. GHK-Cu is not FDA approved and not on the 503A bulks list, so no pharmacy has a lawful basis to compound the mix. [11] [16]

Enforcement is uneven. FDA mostly acts through warning letters to compounders and online sellers, Category 2 safety listings, and import alerts that let it detain shipments, rather than stopping every pharmacy. State pharmacy boards oversee pharmacies day to day, and their rules differ. [16] [17] [18] [19] [20]

What changes for you

• No FDA review of the product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [20]
• Identity, purity, sterility, and dose accuracy can vary from batch to batch. [16]
• Insurance rarely covers it, so you usually pay cash.
• For tested athletes, GLOW contains at least one ingredient that is prohibited at all times on the WADA list. [13]

What to check

These checks lower some risks, but they do not make an unlawfully compounded product lawful or safe. Check for:

• A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [20]
• A real evaluation by a licensed prescriber, not just an online form.
• A certificate of analysis for the specific batch.

Compare the ingredients

• BPC-157 vs GHK-Cu
• BPC-157 vs TB-500
• TB-500 vs GHK-Cu
• BPC-157 vs ARA-290 (cibinetide)
• BPC-157 vs KPV
• Thymosin alpha-1 vs TB-500 (thymosin beta-4)

Blends that share an ingredient

• KLOW: KLOW is GLOW plus KPV: GHK-Cu, BPC-157, TB-500, and KPV in one vial. No study has tested it, and injectable GHK-Cu has no lawful path.
• Wolverine stack: The Wolverine stack pairs BPC-157 and TB-500 for injury recovery. No study has tested the pair, and both await an FDA final rule after the July 2026 vote.

Frequently asked questions

From the blog

• Klow vs Glow peptide: what KPV adds and what is known

  Klow is the Glow blend (GHK-Cu, BPC-157, TB-500) plus KPV. Each ingredient compared, what KPV is claimed to add, how both relate to the Wolverine stack, and why no study tests either blend.

• Copper peptides for hair: what the studies show

  Does GHK-Cu help with hair growth? Copper peptides enlarge hair follicles in lab and mouse studies, but no randomized trial of GHK-Cu alone for hair loss exists. How they compare with minoxidil.

• Peptide before and after: trial results vs marketing photos

  Measured peptide before and after results: GLP-1 weight change, tesamorelin visceral fat, and regain after stopping, compared with Glow, GHK-Cu, BPC-157, and Wolverine claims.

• Topical vs injectable GHK-Cu: what the evidence shows

  Topical GHK-Cu has small skin studies and is a lawful cosmetic. Injectable GHK-Cu has no human trial and no lawful compounding path. Evidence, absorption, safety, and legality compared.

• Peptides for women, ranked by human evidence

  GLP-1 drugs, teriparatide, abaloparatide, and Vyleesi (PT-141) have real trials in women. Kisspeptin is research-only and GHK-Cu rests on small skin studies. The ranking and legal status.

• TB-500 vs thymosin beta-4: is it the same peptide?

  TB-500 is not the same molecule as thymosin beta-4. What each one is, which has human data, what is known about capsules and sprays, and what the evidence says about cancer.

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.